SAN DIEGO, June 13, 2019 /PRNewswire/ — Medical Marijuana, Inc. (OTC:MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company’s major investment company Axim Biotech, Inc. (“AXIM”), a world leader in cannabinoid research and product development, has signed a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”). The agreement states that AXIM will supply its patented toothpaste and mouthwash containing cannabidiol (CBD) for Impression’s clinical trial for the treatment of periodontitis.
“Medical Marijuana, Inc. is proud to be a cannabis industry leader. As part of that leadership, we aim to set an example by aiding in the research deeply needed throughout the industry,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “AXIM’s agreement with Impression Healthcare to provide the necessary materials for a
... read more at: https://www.biospace.com/article/releases/medical-marijuana-inc-major-investment-company-axim-biotechnologies-inc-moves-forward-on-oral-healthcare-line-with-cannabinoid-product-supply-agreement/